TrialThe Lancet. Respiratory medicine2025
Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial.
Sanjay Ramakrishnan et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
59 papers cite it
this papertrialcites it